Back to top

vaccines: Archive

Zacks Equity Research

Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

NVONegative Net Change MRKNegative Net Change MRNANegative Net Change CTMXNegative Net Change

Derek Lewis

Bear of the Day: Pfizer (PFE)

Negative earnings estimate revisions from analysts and weakening sales post-pandemic paint a challenging picture for the company's shares in the near term.

PFENegative Net Change

Zacks Equity Research

Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

MRKNegative Net Change MRNANegative Net Change SRPTNegative Net Change CTMXNegative Net Change